171 related articles for article (PubMed ID: 15756010)
41. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
; Fouladi M; Furman WL; Chin T; Freeman BB; Dudkin L; Stewart CF; Krailo MD; Speights R; Ingle AM; Houghton PJ; Wright J; Adamson PC; Blaney SM
J Clin Oncol; 2006 Aug; 24(22):3678-85. PubMed ID: 16877737
[TBL] [Abstract][Full Text] [Related]
42. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
[TBL] [Abstract][Full Text] [Related]
43. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
[TBL] [Abstract][Full Text] [Related]
44. Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101.
Adamson PC; Blaney SM; Widemann BC; Kitchen B; Murphy RF; Hannah AL; Cropp GF; Patel M; Gillespie AF; Whitcomb PG; Balis FM
Cancer Chemother Pharmacol; 2004 Jun; 53(6):482-8. PubMed ID: 14999430
[TBL] [Abstract][Full Text] [Related]
45. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
Cunningham C; Appleman LJ; Kirvan-Visovatti M; Ryan DP; Regan E; Vukelja S; Bonate PL; Ruvuna F; Fram RJ; Jekunen A; Weitman S; Hammond LA; Eder JP
Clin Cancer Res; 2005 Nov; 11(21):7825-33. PubMed ID: 16278405
[TBL] [Abstract][Full Text] [Related]
46. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
[TBL] [Abstract][Full Text] [Related]
47. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.
de Jonge MJ; van der Gaast A; Planting AS; van Doorn L; Lems A; Boot I; Wanders J; Satomi M; Verweij J
Clin Cancer Res; 2005 May; 11(10):3806-13. PubMed ID: 15897580
[TBL] [Abstract][Full Text] [Related]
48. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
Papadopoulos KP; Goel S; Beeram M; Wong A; Desai K; Haigentz M; Milián ML; Mani S; Tolcher A; Lalani AS; Sarantopoulos J
Clin Cancer Res; 2008 Nov; 14(21):7110-5. PubMed ID: 18981010
[TBL] [Abstract][Full Text] [Related]
49. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Amato RJ; Hernandez-McClain J; Henary H
Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
[TBL] [Abstract][Full Text] [Related]
50. Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer.
Olver I; Keefe D; Myers M
Intern Med J; 2005 Jul; 35(7):405-8. PubMed ID: 15958110
[TBL] [Abstract][Full Text] [Related]
51. A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: an Innovative Therapies for Children with Cancer (ITCC) study.
Geoerger B; Estlin EJ; Aerts I; Kearns P; Gibson B; Corradini N; Doz F; Lardelli P; Miguel BD; Soto A; Prados R; Vassal G
Eur J Cancer; 2012 Feb; 48(3):289-96. PubMed ID: 22119199
[TBL] [Abstract][Full Text] [Related]
52. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
Plummer R; Vidal L; Griffin M; Lesley M; de Bono J; Coulthard S; Sludden J; Siu LL; Chen EX; Oza AM; Reid GK; McLeod AR; Besterman JM; Lee C; Judson I; Calvert H; Boddy AV
Clin Cancer Res; 2009 May; 15(9):3177-83. PubMed ID: 19383817
[TBL] [Abstract][Full Text] [Related]
53. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
Dean E; Jodrell D; Connolly K; Danson S; Jolivet J; Durkin J; Morris S; Jowle D; Ward T; Cummings J; Dickinson G; Aarons L; Lacasse E; Robson L; Dive C; Ranson M
J Clin Oncol; 2009 Apr; 27(10):1660-6. PubMed ID: 19237630
[TBL] [Abstract][Full Text] [Related]
54. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
55. A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients.
Grem JL; Harold N; Keith B; Chen AP; Kao V; Takimoto CH; Hamilton JM; Pang J; Pace M; Jasser GB; Quinn MG; Monahan BP
Clin Cancer Res; 2002 Jul; 8(7):2149-56. PubMed ID: 12114415
[TBL] [Abstract][Full Text] [Related]
56. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
[TBL] [Abstract][Full Text] [Related]
57. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
[TBL] [Abstract][Full Text] [Related]
58. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
[TBL] [Abstract][Full Text] [Related]
59. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
60. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
Nakabayashi M; Xie W; Regan MM; Jackman DM; Kantoff PW; Oh WK
Cancer; 2006 Sep; 107(5):975-81. PubMed ID: 16862573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]